Eledon Pharmaceuticals, Inc.
ELDN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001404281
No open-market purchases or sales by Eledon Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $184.6M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $178.6M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +42 vs. previous quarter
- 161
- 13F valueReported value at the end of Q2 2026
- $184.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$45.6M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 8.25M
- Shares sold short
- Change
- +356.5K
- +4.5% vs. previous
- Days to cover
- 7.51
- At average daily volume
Superinvestors holding ELDN, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ELDN at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Eledon Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 31, 2024 (view filing)5:52 PM ET | Oct 29 | 2 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchaseCommon Stock, $0.001 par value | +4.75M | $3.65 | +$17.3M | –838.5K after | Derivative3 lots |
| May 13, 2024 (view filing)5:04 PM ET | May 9 | 4 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchaseCommon Stock, $0.001 par value | +1.93M | – | – | New position220.5K after | 3 lots |
| May 13, 2024 (view filing)5:04 PM ET | May 9 | 4 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchaseCommon Stock, $0.001 par value | +5.93M | – | – | –232.1K after | Derivative3 lots |
| May 9, 2023 (view filing)8:25 PM ET | May 5 | 4 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchaseCommon Stock, $0.001 par value | +1.98M | – | – | New position145.0K after | 3 lots |
| May 9, 2023 (view filing)8:25 PM ET | May 5 | 4 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchaseCommon Stock, $0.001 par value | +9.59M | – | – | –252.3K after | Derivative6 lots |
| Nov 23, 2022 (view filing) | Nov 23 | Same day | Perrin StevenPresident | PPurchase | +1.00K | $2.60 | +$2.60K | New position1.00K after | |
| Dec 21, 2021 (view filing) | Dec 20 | 1 day | Gros David-Alexandre CChief Executive Officer | PPurchase | +2.00K | $4.48 | +$8.96K | +28.6%9.00K after | |
| Aug 19, 2021 (view filing) | Aug 17 | 2 days | Gros David-Alexandre CChief Executive Officer | PPurchase | +4.00K | $6.21 | +$24.8K | +133.3%7.00K after |
Top 10 13F holders, Q2 2026
See all 161 holdersThe largest institutional positions in Eledon Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BVF Inc | 6,293,282 | $24.8M | 0.63% | 00.0% | Unchanged |
| BlackRock, Inc. | 5,123,842 | $20.2M | 0.00% | +741,597+16.9% | Added |
| Defilade Capital Management, L.P. | 3,525,338 | $13.9M | 1.86% | −38,789−1.1% | Reduced |
| Vanguard Capital Management LLC | 3,417,223 | $13.5M | 0.00% | +124,089+3.8% | Added |
| Goldman Sachs Group Inc | 2,510,308 | $9.89M | 0.00% | +2,140,218+578.3% | Added |
| Ensign Peak Advisors, Inc | 2,101,224 | $8.28M | 0.01% | −363,695−14.8% | Reduced |
| Geode Capital Management, LLC | 1,956,601 | $7.71M | 0.00% | +164,818+9.2% | Added |
| Catalio Capital Management, LP | 1,695,071 | $6.68M | 1.26% | +55,255+3.4% | Added |
| State Street Corp | 1,621,969 | $6.39M | 0.00% | +467,298+40.5% | Added |
| Zimmer Partners, LP | 1,596,599 | $6.29M | 0.15% | −278,401−14.8% | Reduced |
Holders of 5% or more of ELDN
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Eledon Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Biotechnology Value Fund L P | 13G/A | 9.99%7.87M shares | – | Feb 16, 20218 filings | May 15, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.80%4.38M shares | +1.20 ppfrom 4.60% | Jul 17, 20253 filings | Apr 27, 2026 | SEC |